Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases (PMD), today announced positive ...